Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 916-920

  Truini, A ^a,b   Biasiotta, A ^a   Di Stefano, G ^a   la Cesa, S ^a   Leone, C ^a   Cartoni, C ^a   Federico, V ^a   Petrucci, M T ^a   Cruccu, G ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Bortezomib; Laser evoked potentials; Multiple myeloma; Nerve conduction study; Painful neuropathy; Palmitoylethanolamide; Thalidomide

Indexed keywords

ANALGESIC AGENT; BORTEZOMIB; PALMIDROL; THALIDOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; EVOKED RESPONSE; FEMALE; HEAT SENSITIVITY; HUMAN; LASER EVOKED POTENTIAL; MALE; MOTOR NERVE CONDUCTION; MULTIPLE MYELOMA; MYELINATED NERVE; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; SENSORY NERVE CONDUCTION;

EID: 84857742677     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219307     Document Type: Article

References (37)

1. Delforge, M.; Bladé, J.; Dimopoulos, M.A.; Facon, T.; Kropff, M.; Ludwig, H.; Palumbo, A.; Van Damme, P.; San-Miguel, J.F.; Sonneveld, P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol., 2010, 11,1086-1095.
2. Wolf, S.; Barton, D.; Kottschade, L.; Grothey, A.; Loprinzi, C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer, 2008, 44, 1507-1515.
3. Tariman, J.D.; Love, G.; McCullagh, E.; Sandifer, S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin. J. Oncol. Nurs., 2008, 12, 29-36.
4. Thacker, M.A.; Clark, A.K.; Marchand, F.; McMahon, S.B. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth. Analg., 2007, 105(3), 838-847.
5. Machelska, H. Dual peripheral actions of immune cells in neuropathic pain. Arch. Immunol. Ther. Exp. (Warsz.), 2011, 59(1), 11-24.
6. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions, 1993, 39, C145-C147.
7. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA, 1995, 92, 3376-3380.
8. Granberg, M.; Fowler, C.J.; Jacobsson, S.O. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leukaemic cells. Naunyn Schmiedebergs Arch. Pharmacol., 2001, 364(1), 66-73.
9. Cerrato, S.; Brazis, P.; della Valle, M.F.; Miolo, A.; Puigdemont, A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet. Immunol. Immunopathol., 2010, 133(1), 9-15.
10. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain, 2008, 139(3),541-550.
11. Loría, F.; Petrosino, S.; Mestre, L.; Spagnolo, A.; Correa, F.; Hernangómez, M.; Guaza, C.; Di Marzo, V.; Docagne, F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci., 2008, 28(4), 633-641.
12. Genovese, T.; Esposito, E.; Mazzon, E.; Di Paola, R.; Meli, R.; Bramanti, P.; Piomelli, D.; Calignano, A.; Cuzzocrea, S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther., 2008, 326(1),12-23.
13. Esposito, E.; Paterniti, I.; Mazzon, E.; Genovese, T.; Di Paola, R.; Galuppo, M.; Cuzzocrea, S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun., 2011, 25(6),1099-1112.
14. Jack, D.B. Aliamides: a new approach to the treatment of inflammation. Drug News Perspect., 1996, 9(2), 93-98.
15. Calabrò, R.S.; Gervasi, G.; Marino, S.; Mondo, P.N.; Bramanti, P. Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med., 2010, 11(5),781-784
16. Indraccolo, U.; Barbieri, F. Effect of palmitoylethanolamidepolydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 150(1), 76-79.
17. Cobellis, L.; Castaldi, M.A.; Giordano, V.; Trabucco, E.; De Franciscis, P.; Torella, M.; Colacurci, N. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)- transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 158(1), 82-86.
18. Conigliaro, R.; Drago, V.; Foster, P.S.; Schievano, C.; Di Marzo, V. Use of the palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med., 2011, 101(2),141-147.
19. England, J.D.; Gronseth, G.S.; Franklin, G.; Miller, R.G.; Asbury, A.K.; Carter, G.T.; Cohen, J.A.; Fisher, M.A.; Howard, J.F.; Kinsella, L.J.; Latov, N.; Lewis, R.A.; Low, P.A.; Sumner, A.J. American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology, 2005, 64,199-207.
20. Bouhassira, D.; Attal, N.; Alchaar, H.; Boureau, F.; Brochet, B.; Bruxelle, J.; Cunin, G.; Fermanian, J.; Ginies, P.; Grun-Overdyking, A.; Jafari-Schluep, H.; Lantéri-Minet, M.; Laurent, B.; Mick, G.; Serrie, A.; Valade, D.; Vicaut, E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 2005, 114, 29-36.
21. Cruccu, G.; Anand, P.; Attal, N.; Garcia-Larrea, L.; Haanpää, M.; Jørum, E.; Serra, J.; Jensen, T.S. EFNS guidelines on neuropathic pain assessment. Eur. J. Neurol., 2004, 11, 153-162.
22. Cruccu, G.; Pennisi, E.; Truini, A.; Iannetti, G.D.; Romaniello, A.; Le Pera, D.; De Armas, L.; Leandri, M.; Manfredi, M.; Valeriani, M. Unmyelinated trigeminal pathways as assessed by laser stimuli in humans. Brain, 2003, 126, 2246-2256.
23. Caruso, G.; Eisen, A.; Stålberg, E.; Kimura, J.; Mamoli, B.; Dengler, R.; Santoro, L.; Hopf, H.C. Clinical EMG and glossary of terms most commonly used by clinical electromyographers. The International Federation of Clinical Neurophysiology. Electroencephalogr. Clin. Neurophysiol. Suppl., 1999, 52,189-198.
24. Cruccu, G.; Aminoff, M.J.; Curio, G.; Guerit, J.M.; Kakigi, R.; Mauguiere, F.; Rossini, P.M.; Treede, R.D.; Garcia-Larrea, L. Recommendations for the clinical use of somatosensory-evoked potentials. Clin. Neurophysiol., 2008, 119, 1705-1719.
25. Mileshkin, L.; Stark, R.; Day, B.; Seymour, J.F.; Zeldis, J.B.; Prince, H.M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J. Clin Oncol., 2006, 24, 4507-4514.
26. Plasmati, R.; Pastorelli F.; Cavo, M.; Petracci, E.; Zamagni, E.; Tosi, P.; Cangini, D.; Tacchetti, P.; Salvi, F.; Bartolomei, I.; Michelucci, R.; Tassinari, C.A. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology, 2007, 69, 573-581.
27. Cruccu, G.; Sommer, C.; Anand, P.; Attal, N.; Baron, R.; Garcia-Larrea, L.; Haanpaa, M.; Jensen, T.S.; Serra, J.; Treede, R.D. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur. J. Neurol., 2010, 17, 1010-1018.
28. Chaudhry, V.; Cornblath, D.R.; Corse, A.; Freimer, M.; Simmons-O'Brien, E.; Vogelsang, G. Thalidomide-induced neuropathy. Neurology, 2002, 59, 1872-1875.
29. Richardson, P.G.; Xie, W.; Mitsiades, C.; Chanan-Khan, A.A.; Lonia, l. S.; Hassoun, H.; Avigan, D.E.; Oaklander, A.L.; Kuter, D.J.; Wen, P.Y.; Kesari, S.; Briemberg, H.R.; Schlossman, R.L.; Munshi, N.C.; Heffner, L.T.; Doss, D.; Esseltine, D.L.; Welle, E.; Anderson, K.C.; Amato, A.A. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol., 2009, 21, 3518-3525.
30. Farquhar-Smith, W.P.; Jaggar, S.I.; Rice, A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB (1) and CB (2)-like receptors. Pain, 2002, 97(1-2), 11-21.
31. Mohty, B.; El-Cheikh, J.; Yakoub-Agha, I.; Moreau, P.; Harousseau, J.L.; Mohty, M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 2010, 95(2), 311-319.
32. Lundborg, G.; Myers, R.; Powell, H. Nerve compression injury and increased endoneurial fluid pressure: a miniature compartment syndrome. J. Neurol. Neurosurg. Psychiatry, 1983, 46, 1119-1124.
33. Hayashi, R.; Xiao, W.; Kawamoto, M.; Yuge, O.; Bennett, G.J. Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy. J. Pharmacol. Sci., 2008, 106, 559-565.
34. Mizisin, A.P.; Weerasuriya, A. Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol., 2011, 121, 291-312.
35. Levi-Montalcini, R.; Skaper, S.D.; Dal Toso, R.; Petrelli, L.; Leon, A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci., 1996, 19, 514-520.
36. Duncan, R.S.; Chapman, K.D.; Koulen, P. The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol. Neurodegener., 2009, 4, 50.
37. Koch, M.; Kreutz, S.; Böttger, C.; Benz, A.; Maronde, E.; Ghadban, C.; Korf, H.W.; Dehghani, F. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferatoractivated receptor-alpha. Neurotox. Res., 2011, 19(2), 330-340.